Skip to main content
Equibles

Shaun Bagai

CEO

RenovoRx, Inc. (RNXT)

Board Member

RenovoRx, Inc. (RNXT)

Equibles does not estimate personal net worth.

Get an email with a short summary when RenovoRx, Inc. publishes a filing, an earnings call transcript or a press release.

Get RNXT alerts

About Shaun Bagai

Shaun Bagai is recorded as CEO and Board Member at RenovoRx, Inc. (RNXT). The proxy statement of RenovoRx, Inc. reports total compensation of $1,232,317 for Shaun Bagai in fiscal 2025, including a base salary of $583,441. Disclosed compensation is on record for 4 fiscal years. Shaun Bagai has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for RenovoRx, Inc. on August 12, 2026. RenovoRx, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at RenovoRx, Inc. includes Shaun R. Bagai (CEO and Board Member), Ramtin Agah (Chairman), Ramtin Agah, M.D. (Chairman) and 7 others.

Shaun Bagai on recent calls

“Over the past several quarters, we set out three milestones for Renovar X. In this quarter, we delivered on all three. First, revenue growth. The second quarter was a record revenue quarter, our strongest to date.”
CEO, Second Quarter 2026 Financial Results Conference Call ·
“Thank you for the introduction, and thank you for the opportunity here, and thanks everyone for joining in. Sean Guy here, CEO of RenovoRx, and I'm also joined by my CFO, Chief Financial Officer, Mark Boll, who will chime in at the appropriate times.”
CEO, iAccess Alpha Virtual Best Ideas Summer Investement Conference 2026 ·
“When we spoke with you in late March, we told you that Q1-2026 would be our strongest revenue quarter yet. Today, I am pleased to confirm that we delivered on that commitment.”
CEO, RenovoRx, Inc. Q1 FY2026 Earnings Call ·
“Before I walk to our results, I want to acknowledge two important developments in our leadership structure. As we recently announced, Dr. Ramton Agha, our founder and inventor of our patented TAMP therapy platform, has transitioned to the role of Executive Chairman.”
CEO, RenovoRx, Inc. Q4 FY2025 Earnings Call ·
“Building on our clinical progress, we are also seeing strong commercial momentum for RenovoCath as a standalone medical device.”
CEO, RenovoRx, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at RenovoRx, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 RenovoRx, Inc. (RNXT) $583,441 $1,232,317
2024 RenovoRx, Inc. (RNXT) $520,000 $1,226,050
2023 RenovoRx, Inc. (RNXT) $520,000 $936,779
2022 RenovoRx, Inc. (RNXT) $495,000 $841,074

Recent activity